Teladoc Health (NYSE:TDOC) Given New $6.00 Price Target at TD Cowen

Teladoc Health (NYSE:TDOC) had its price objective cut by TD Cowen from $8.00 to $6.00 in a report published on Thursday,Benzinga reports. They currently have a hold rating on the health services provider’s stock.

Several other brokerages have also issued reports on TDOC. Evercore decreased their target price on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a research report on Thursday, October 30th. Stifel Nicolaus reduced their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. BMO Capital Markets assumed coverage on shares of Teladoc Health in a research note on Thursday, November 13th. They issued a “market perform” rating and a $8.00 target price on the stock. Finally, Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Thursday. Four equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $7.80.

Teladoc Health Trading Up 15.1%

NYSE:TDOC opened at $5.35 on Thursday. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $10.02. The firm has a 50-day moving average price of $6.03 and a two-hundred day moving average price of $7.21. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The firm has a market cap of $949.46 million, a price-to-earnings ratio of -4.69 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $642.27 million for the quarter, compared to the consensus estimate of $635.33 million. Teladoc Health had a negative return on equity of 9.09% and a negative net margin of 7.92%.The company’s revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, equities analysts expect that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, insider Adam C. Vandervoort sold 5,720 shares of Teladoc Health stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total value of $42,842.80. Following the completion of the transaction, the insider owned 80,732 shares in the company, valued at $604,682.68. This trade represents a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Charles Divita III sold 17,138 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares in the company, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,288 shares of company stock worth $251,684 over the last ninety days. Company insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

A number of large investors have recently made changes to their positions in the stock. Allianz Asset Management GmbH lifted its holdings in shares of Teladoc Health by 189.2% in the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after buying an additional 1,059,458 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Teladoc Health during the 2nd quarter worth approximately $2,722,000. Jupiter Asset Management Ltd. purchased a new stake in Teladoc Health in the 3rd quarter worth approximately $7,576,000. Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in Teladoc Health by 23.1% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 212,933 shares of the health services provider’s stock valued at $1,841,000 after purchasing an additional 39,956 shares during the period. Finally, Empowered Funds LLC bought a new position in Teladoc Health in the 2nd quarter valued at $5,040,000. 76.82% of the stock is owned by institutional investors.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss: Teladoc reported revenue of $642.3M (above estimates) and GAAP loss per share of $0.14 (better than consensus), driven by international growth and strength in Integrated Care; investors view the improved bottom line as a near-term positive. Teladoc Tops Q4 Earnings Estimates on International Growth & Lower Costs
• Positive Sentiment: Selective analyst support: Some firms are staying constructive (Bank of America upgraded to Buy, Piper Sandler reaffirmed Overweight, Canaccord remains a Buy despite lowering its PT), which bolsters demand from buyers who focus on recovery potential. Demystifying Teladoc Health: Insights From 8 Analyst Reviews
• Neutral Sentiment: Midterm growth roadmap: Management projects FY2026 revenue of roughly $2.47B–$2.59B and emphasized investments in AI, insurance relationships and international expansion — initiatives that support longer-term upside but will take time to materialize. Teladoc projects $2.47B–$2.59B revenue in 2026
• Negative Sentiment: Cautious forward guidance: Q1 2026 revenue guidance ($598M–$620M) and EPS guidance (-$0.45 to -$0.35) came in below Wall Street expectations, and FY EPS guidance (-$1.10 to -$0.70) is wider/weaker than consensus — a key reason for mixed investor reactions despite the quarter’s beat. Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Analyst price-target cuts: Several firms trimmed price targets (BMO, TD Cowen, Stifel, Wells Fargo, Leerink) and moved to Market Perform/Hold ratings in response to the softer outlook, adding selling pressure for investors focused on nearer-term valuation and earnings visibility. Analyst price-target updates

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.